IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on Immune Functions in Healthy Adults in a Randomized Controlled Trial

  • Hwang, Hee-Jin (Department of Family Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine) ;
  • Sohn, Ki-Young (ENZYCHEM Lifesciences) ;
  • Han, Yong-Hae (ENZYCHEM Lifesciences) ;
  • Chong, Saeho (ENZYCHEM Lifesciences) ;
  • Yoon, Sun Young (ENZYCHEM Lifesciences) ;
  • Kim, Young-Jun (Biomedical Translational Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Jeong, Jinseoun (Biomedical Translational Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Kim, Sang-Hwan (Institute for Geriatric Medicine, Yonsei Woori Geriatric Hospital) ;
  • Kim, Jae Wha (Biomedical Translational Research Center, Korea Research Institute of Bioscience and Biotechnology)
  • Received : 2015.05.06
  • Accepted : 2015.06.08
  • Published : 2015.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

We previously reported that 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) accelerates hematopoiesis and has an improving effect on animal disease models such as sepsis and asthma. The effects of PLAG supplementation on immune modulation were assessed in healthy men and women. The objective was to evaluate the effects of PLAG supplementation on immune regulatory functions such as activities of immune cells and cytokine production. A randomized double blind placebo-controlled trial was conducted. Seventy-five participants were assigned to one of two groups; all participants had an appropriate number of white blood cells on the testing day. The PLAG group (n=27) received oral PLAG supplements and the control group (n=22) received oral soybean oil supplements. IL-4 and IL-6 production by peripheral blood mononuclear cells (PBMC) were lower (p<0.001 and p<0.001, respectively) with PLAG than with soybean oil. However, the production of IL-2 and IFN-$\gamma$ by PBMC was unaltered with PLAG supplementation. The B cell proliferation decreased significantly in the PLAG group compared to the soybean oil control (p<0.05). The intake of PLAG in healthy adults for 4 weeks was deemed safe. These data suggest that PLAG has an immunomodulatory function that inhibits the excessive immune activity of immunological disorders such as atopic and autoimmune diseases. PLAG could improve the condition of these diseases safely as a health food supplement.

Keywords

References

  1. Wu, F., H. Li, L. Jin, X. Li, Y. Ma, J. You, S. Li, and Y. Xu. 2013. Deer antler base as a traditional Chinese medicine: a review of its traditional uses, chemistry and pharmacology. J. Ethnopharmacol. 145: 403-415. https://doi.org/10.1016/j.jep.2012.12.008
  2. Gilbey, A., and J. D. Perezgonzalez. 2012. Health benefits of deer and elk velvet antler supplements: a systematic review of randomised controlled studies. N. Z. Med. J. 125: 80-86.
  3. Allen, M., K. Oberle, M. Grace, A. Russell, and A. J. Adewale. 2008. A randomized clinical trial of elk velvet antler in rheumatoid arthritis. Biol. Res. Nurs. 9: 254-261. https://doi.org/10.1177/1099800407309505
  4. Yang, H. O., J. S. Park, S. H. Cho, J. Y. Yoon, M. G. Kim, G. J. Jhon, S. Y. Han, and S. H. Kim. 2004. Stimulatory effects of monoacetyldiglycerides on hematopoiesis. Biol. Pharm. Bull. 27: 1121-1125. https://doi.org/10.1248/bpb.27.1121
  5. Kleiman, R., R. W. Miller, F. R. Earle, and I. A. Wolff. 1966. Optically active aceto-triglycerides of oil fromEuonymus verrucosus seed. Lipids 1: 286-287. https://doi.org/10.1007/BF02531619
  6. Myher, J. J., A. Kuksis, L. Marai, and P. Sandra. 1988. Identification of the more complex triacylglycerols in bovine milk fat by gas chromatography-mass spectrometry using polar capillary columns. J. Chromatogr. 452: 93-118. https://doi.org/10.1016/S0021-9673(01)81440-0
  7. Limb, J. K., Y. H. Kim, S. Y. Han, and G. J. Jhon. 1999. Isolation and characterization of monoacetyldiglycerides from bovine udder. J. Lipid Res. 40: 2169-2176.
  8. Yang, H. O., S. H. Kim, S. H. Cho, M. G. Kim, J. Y. Seo, J. S. Park, G. J. Jhon, and S. Y. Han. 2004. Purification and structural determination of hematopoietic stem cell-stimulating monoacetyldiglycerides from Cervus nippon (deer antler). Chem. Pharm. Bull. (Tokyo) 52: 874-878. https://doi.org/10.1248/cpb.52.874
  9. Kim, M. H., H. M. Chang, T. W. Kim, S. K. Lee, J. S. Park, Y. H. Kim, T. Y. Lee, S. J. Jang, C. W. Suh, T. S. Lee, S. H. Kim, and S. G. Lee. 2009. EC-18, a synthetic monoacetyldiacylglyceride, inhibits hematogenous metastasis of KIGB-5 biliary cancer cell in hamster model. J. Korean Med. Sci. 24: 474-480. https://doi.org/10.3346/jkms.2009.24.3.474
  10. Hong, J. J., Y. Koh, J. S. Park, H. D. Jung, S. H. Kim, T. S. Lee, and M. M. Badellino. 2010. Enteral administration of a synthetic monoacetyldiglyceride improves survival in a murine model of abdominal sepsis. J. Trauma 68: 62-68. https://doi.org/10.1097/TA.0b013e3181c3fede
  11. Shin, I. S., N. R. Shin, C. M. Jeon, O. K. Kwon, K. Y. Sohn, T. S. Lee, J. W. Kim, K. S. Ahn, and S. R. Oh. 2014. EC-18, a synthetic monoacetyldiglyceride (1-palmitoyl-2-linoleoyl-3-acetylglycerol), attenuates the asthmatic response in an aluminum hydroxide/ovalbumin-induced model of asthma. Int. Immunopharmacol. 18: 116-123. https://doi.org/10.1016/j.intimp.2013.11.006
  12. Barrett, N. A., and K. F. Austen. 2009. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 31: 425-437. https://doi.org/10.1016/j.immuni.2009.08.014
  13. Doherty, T., and D. Broide. 2007. Cytokines and growth factors in airway remodeling in asthma. Curr. Opin. Immunol. 19: 676-680. https://doi.org/10.1016/j.coi.2007.07.017
  14. Walford, H. H., and T. A. Doherty. 2014. Diagnosis and management of eosinophilic asthma: a US perspective. J .Asthma Allergy 7: 53-65.
  15. Isidoro-Garcia, M., I. Davila, E. Laffond, E. Moreno, F. Lorente, and R. Gonzalez-Sarmiento. 2005. Interleukin-4 (IL4) and Interleukin-4 receptor (IL4RA) polymorphisms in asthma: a case control study. Clin. Mol. Allergy 3: 15. https://doi.org/10.1186/1476-7961-3-15
  16. Kumar, V. A., A. K. Abbas, and J. C. Aster. 2012. Inflammation and Repair. Basic Pathology, 9th ed. Elsevier, Philadelphia, PA. p.53
  17. Gor, D. O., N. R. Rose, and N. S. Greenspan. 2003. TH1-TH2: a procrustean paradigm. Nat. Immunol. 4: 503-505.
  18. Romagnani, S. 1995. Biology of human TH1 and TH2 cells. J. Clin. Immunol. 15: 121-129. https://doi.org/10.1007/BF01543103
  19. Cher, D. J., and T. R. Mosmann. 1987. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J. Immunol. 138: 3688-3694.
  20. O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8: 275-283. https://doi.org/10.1016/S1074-7613(00)80533-6
  21. Onoe, K., Y. Yanagawa, K. Minami, N. Iijima, and K. Iwabuchi. 2007. Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol. Res. 38: 319-332. https://doi.org/10.1007/s12026-007-0011-5
  22. Kidd, P. 2003. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8: 223-246.
  23. Kaminogawa, S., and M. Nanno. 2004. Modulation of Immune Functions by Foods. Evid. Based Complement Alternat. Med. 1: 241-250. https://doi.org/10.1093/ecam/neh042
  24. Kristiansen, O. P., and T. Mandrup-Poulsen. 2005. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 54 Suppl 2: S114-S124. https://doi.org/10.2337/diabetes.54.suppl_2.S114
  25. Dubinski, A., and Z. Zdrojewicz. 2007. The role of interleukin-6 in development and progression of atherosclerosis. Pol. Merkur. Lekarski 22: 291-294.
  26. Swardfager, W., K. Lanctot, L. Rothenburg, A. Wong, J. Cappell, and N. Herrmann. 2010. A meta-analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 68: 930-941. https://doi.org/10.1016/j.biopsych.2010.06.012
  27. Tackey, E., P. E. Lipsky, and G. G. Illei. 2004. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13: 339-343. https://doi.org/10.1191/0961203304lu1023oa
  28. Nishimoto, N. 2006. Interleukin-6 in rheumatoid arthritis. Curr. Opin. Rheumatol. 18: 277-281. https://doi.org/10.1097/01.bor.0000218949.19860.d1
  29. Song, M., and J. A. Kellum. 2005. Interleukin-6. Crit. Care Med. 33: S463-S465. https://doi.org/10.1097/01.CCM.0000186784.62662.A1
  30. Smith, P. C., A. Hobisch, D. L. Lin, Z. Culig, and E. T. Keller. 2001. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 12: 33-40. https://doi.org/10.1016/S1359-6101(00)00021-6
  31. Tschaikowsky, K., M. Hedwig-Geissing, G. G. Braun, and M. Radespiel-Troeger. 2011. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsisJ. Crit. Care 26: 54-64. https://doi.org/10.1016/j.jcrc.2010.04.011
  32. Zipfel, P. F., and C. Skerka. 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9: 729-740. https://doi.org/10.1038/nri2620
  33. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797. https://doi.org/10.1038/ni.1923
  34. Pio, R., D. Ajona, and J. D. Lambris. 2013. Complement inhibition in cancer therapy. Semin. Immunol. 25: 54-64. https://doi.org/10.1016/j.smim.2013.04.001
  35. Risitano, A. M., D. Ricklin, Y. Huang, E. S. Reis, H. Chen, P. Ricci, Z. Lin, C. Pascariello, M. Raia, M. Sica, V. L. Del, F. Pane, F. Lupu, R. Notaro, R. R. Resuello, R. A. DeAngelis, and J. D. Lambris. 2014. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 123: 2094-2101. https://doi.org/10.1182/blood-2013-11-536573
  36. Hammond, E. G., L. A. Johnson, C. Su, T. Wang, P. J. White. 2005. Soybean oil. Bailey's Industrial Oil and Fat Products. John Wiley & Sons, Inc. Hoboken, NJ. 2: 13

Cited by

  1. 1‐Palmitoyl‐2‐linoleoyl‐3‐acetyl‐rac‐glycerol ameliorates chemoradiation‐induced oral mucositis vol.26, pp.1, 2020, https://doi.org/10.1111/odi.13224